Medicine
Praxbind 2500 mg/50 mL injection
Praxbind 2500 mg/50 mL injection is a prescription medicine containing Idarucizumab for intravenous use, marketed by Boehringer Ingelheim Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store PRAXBIND vials in the refrigerator at 2°C to 8°C (36°F to 46°F) in the…
Key facts
- Active ingredient (INN)
- Idarucizumab
- Brand
- Praxbind
- Strength
- 2500 mg/50 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 2 vials of 50 mL
- Marketing authorisation holder
- Boehringer Ingelheim Pharmaceuticals
- Manufacturer
- Boehringer Ingelheim Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store PRAXBIND vials in the refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. PRAXBIND vials may be stored at room temperature, 25°C (77°F), for up to 48 hours in the original carton to protect from light. PRAXBIND vials may be stored at room temperature, 25°C (77°F), out of the carton and exposed to light but must be used within 6 hours.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V03AB37 Idarucizumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 21 October 2015
- Identifiers
- RxCUI 1716195, 1716200DailyMed set ID c7400f8a-dcf4-a6df-6d07-983081b1bf34NDC 0597-0197Application BLA761025
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 vial, single-dose in 1 carton / 50 mL in 1 vial, single-dose | 0597-0197-05 | Boehringer Ingelheim Pharmaceuticals | 21 October 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Idarucizumab is a humanized monoclonal antibody fragment indicated in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed. It is available as injection for intravenous use. MedsAcross supplies Idarucizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about IdarucizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Praxbind prescribing information (Boehringer Ingelheim Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Praxbind: European public assessment report (EPAR) · European Medicines Agency
Need Praxbind 2500 mg/50 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.